US Influenza Market: By Drug Class (Anti-viral Drugs, Vaccines), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Others) and Country  

US Influenza Market size was valued at US$ 2.7 billion in 2023 and is poised to grow at a CAGR of 16.2% from 2024-2030. Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneezing, or talking. The common symptoms that occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, and fatigue, in some cases, people may have vomiting and diarrhea.

The complications of the disease may include ear infections, bacterial pneumonia, dehydration, and sinus infections, and sometimes it leads to congestive heart failure and asthma. Influenza commonly occurs in the geriatric population and children less than 5 years of age. The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate.

Influenza vaccines are key revenue contributors to the growth of the U.S. influenza market. The U.S. influenza market is in the growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from the U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of the U.S. influenza market.

For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from the U.S. Food and Drug Administration for Flucelvax Quadrivalent, which was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from the U.S. Food and Drug Administration for fluvial Quadrivalent to include use in children aged six months or older.